 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 292605-14-2 |
| Molecular formula(MF) | C15H14O3S2 |
| Molecular Weight(MW): | 306.40 |
| Alias |
| In vitro | DMSO | 61 mg/mL (199.08 mM) |
|---|---|---|
| Ethanol | 10 mg/mL warmed (32.63 mM) | |
| Water | <1 mg/mL | |
| In vivo | 4% DMSO+corn oil | 10mg/mL |
| Description | SB-3CT is an effective and selective gelatinase inhibitor with Ki of 13.9 nM and 600 nM for MMP-2 and MMP-9, respectively. | ||||
|---|---|---|---|---|---|
| Targets |
|
||||
| In vitro |
SB-3CT directly inhibits bone marrow endothelial cell invasion and tubule formation in Matrigel in vitro. [3] |
||||
| In vivo | In L-CI.5s T-cell lymphoma model, SB-3CT (5-50 mg/kg/d i.p.) potently inhibit liver metastasis and increases survival of mice. [2] SB-3CT (50 mg/kg/d i.p.) inhibits human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model. [3] In a mouse model of embolus-induced “permanent” focal cerebral ischemia, SB-3CT counteracts degradation of neuronal laminin, protects neurons from ischemic cell death, and ameliorates neurobehavioral outcomes after embolic MCA occlusion. [4] |